key: cord-0256193-m7rv0xez authors: Blasiak, A.; Truong, A. T.; Remus, A.; Hooi, L.; Seah, S. G. K.; Wang, P.; Chye, D. H.; Lim, A. P. C.; Ng, K. T.; Teo, S. T.; Tan, Y.-J.; Allen, D. M.; Chai, L. Y. A.; Chng, W. J.; Lye, D. C. B.; Wong, J. E.-L.; Chan, C. E. Z.; Chow, E. K.-H.; Ho, D. title: The IDentif.AI 2.0 Pandemic Readiness Platform: Rapid Prioritization of Optimized COVID-19 Combination Therapy Regimens date: 2021-07-02 journal: nan DOI: 10.1101/2021.06.23.21259321 sha: 554c60ed00db429dac14bd46f7dd77153d227bd7 doc_id: 256193 cord_uid: m7rv0xez Objectives: We aimed to harness IDentif.AI 2.0, a clinically actionable AI platform to rapidly pinpoint and prioritize optimal combination therapy regimens against COVID-19. Methods: A pool of starting candidate therapies was developed in collaboration with a community of infectious disease clinicians and included EIDD-1931 (metabolite of EIDD-2801), baricitinib, ebselen, selinexor, masitinib, nafamostat mesylate, telaprevir (VX-950), SN-38 (metabolite of irinotecan), imatinib mesylate, remdesivir, lopinavir, and ritonavir. Following the initial drug pool assessment, a focused, 6-drug pool was interrogated at 3 dosing levels per drug representing nearly 10,000 possible combination regimens. IDentif.AI 2.0 paired prospective, experimental validation of multi-drug efficacy on a SARS-CoV-2 live virus (propagated, original strain and B.1.351 variant) and Vero E6 assay with a quadratic optimization workflow. Results: Within 3 weeks, IDentif.AI 2.0 realized a list of combination regimens, ranked by efficacy, for clinical go/no-go regimen recommendations. IDentif.AI 2.0 revealed EIDD-1931 to be a strong candidate upon which multiple drug combinations can be derived. Conclusions: IDentif.AI 2.0 rapidly revealed promising drug combinations for a clinical translation. It pinpointed dose-dependent drug synergy behavior to play a role in trial design and realizing positive treatment outcomes. IDentif.AI 2.0 represents an actionable path towards rapidly optimizing combination therapy following pandemic emergence. COVID-19 drug development has largely focused on repurposing, either through single agent or combination therapy (Group, 2021 Kalil et al., 2021; Mirabelli et al., 2020; Riva et al., 2020) . Clinical trial outcomes of the repurposed candidates were varied (Sheahan et al., 2020; Tekin et al., 2018; White et al., 2021) . While many monotherapies did not mediate substantial clinical benefit, their use in properly designed drug combinations may lead to unforeseen efficacy. Addressing this point is challenging for traditional antiviral susceptibility assays. Therefore, developing new methods that leverage unpredictable drug interactions to resolve the complexity of drug selection and dose-dependent drug synergy is essential. In fact, drug and dose selection are so tightly connected that among a pool of candidate therapies, true optimization often yields combinations of unforeseen but clinically acceptable drugs and doses. Unfortunately, simultaneous drug and dose optimization represents an insurmountable challenge. 12 drugs assessed at 3 dosage levels results in over 500,000 possible combinations. Important strategies for synergy prediction and higher-order drug interaction analysis have been explored (Galindez et al., 2021; Mohapatra et al., 2020; Mongia et al., 2021; Tekin et al., 2018; Zimmer et al., 2016) . To address the challenge of ensuring clinical actionability of the combination design outcome, we developed the IDentif.AI platform, an AI-based workflow for rapid combination therapy development. The first permutation of IDentif.AI used neural networks to reveal that the biological response to therapy can be represented by a smooth surface. Subsequent studies resolved this surface, which can rapidly identify optimal combinations, using a second-order algebraic function, with its coefficients determined through a small number of prospective experiments (Abdulla et al., 2020; Al-Shyoukh et al., 2011; Blasiak et al., 2021; Clemens et al., 2019; Ho, 2020; Ho et al., 2020; Lee et al., 2017; Lim et al., 2020; Mohd Abdul Rashid et al., 2015; Rashid et al., 2018; Silva et al., 2016; Wang et al., 2015; Wong et al., 2008) . This correlation has subsequently been verified in prospective, human studies in infectious disease, cancer therapy, transplant medicine, and other indications (Tan BKJ et al., 2021; Blasiak et al., 2020; de Mel et al., 2020; Kee et al., 2019; Pantuck et al., 2018; Shen et al., 2020; Zarrinpar et al., 2016) . IDentif.AI does not use pre-existing data for algorithm training, in silico modeling, or synergy prediction. Instead, it uses experimental assays to determine the drugs and doses that constitute globally optimized combination regimens. Our previous IDentif.AI studies pinpointed top-ranked combinations (based on inhibition efficacy) mediated by unforeseen drug interactions (Blasiak et al., 2021) . Following this study, we developed IDentif.AI 2.0 to expand the resolution of drug and dose analysis to yield a broader spectrum of clinically actionable combinations. Due to the strong dependence of drug selection and drug dosing on combination therapy optimization, IDentif.AI and IDentif.AI 2.0 utilized clinically relevant dosing levels as reference points for the design of their respective studies. Furthermore, their optimization capabilities have been foundational towards their strong alignment with clinical trial outcomes. In this study (Fig. 1) , a starting pool of candidate therapies that have been or are being evaluated in various COVID-19 clinical settings was developed in consultation with the clinical community (Table 1 , (Beigel et al., 2020; Goldman et al., 2020; Richardson et al., 2020) . IDentif.AI 2.0 implementation on a propagated, original live SARS-CoV-2 strain was completed within 3 weeks. This workflow rapidly pinpointed EIDD-1931 in combination with remdesivir (RDV), EIDD-1931 in combination with baricitinib (BRT), and EIDD-1931 in combination with masitinib (MST) as promising regimens for further development. EIDD-1931/RDV resulted in the highest efficacy and All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 2, 2021. ; https://doi. org/10.1101 org/10. /2021 broad synergy across varying dosing levels. EIDD-1931 in combination with BRT or MST showed a stronger dose-dependence on drug synergy compared to EIDD/RDV. These results were reconfirmed against the SARS-CoV-2 B.1.351 (beta) variant. The results demonstrate the need for dose optimization studies should these regimens be advanced to clinical trials. The resulting highly ranked combinations also demonstrate that EIDD-1931 (and likely the EIDD-2801 prodrug) is a strong candidate upon which multiple drug combinations can be derived (Cox et al., 2020; Sheahan et al., 2020) . IDentif.AI 2.0 did not rely on pre-existing datasets, synergy predictions, or in silico modeling to design these combinations. Instead, it harnessed experimental data from carefully designed drugdose permutations and prospectively executed studies to drive the optimization process to complement existing strategies in the fight against COVID-19 pandemic. These results demonstrate the potential actionability of IDentif.AI 2.0 as an effective go/no-go platform for prioritizing and advancing combination therapies towards further preclinical or clinical development, and clinical decision support system (CDSS). Additional sections can be found in Supplemental Materials and Methods. All experiments with the live SARS-CoV-2 (propagated, original strain and B.1.351variant) were performed in a BSL-3 laboratory. Each treatment was prepared in the culture media and pipetted into the wells of the white 96-well plate in triplicate. 2 x 10 4 Vero E6 cells were added into each well with and without SARS-CoV-2 (100 TCID50) to test viral CPE inhibition and cytotoxicity effects, respectively. The maximum DMSO concentration used in each experimental step and media only served as vehicle controls. Plates were incubated for 72 h before measuring the cell viability via Viral ToxGlo (Promega, G8941) per manufacturer's instructions. Drug cytotoxicity and viral CPE inhibition were calculated, as described previously (Blasiak et al., 2021) . In case no difference was detected between the vehicle and cell only controls, the results from these treatments in each plate were pooled together and served as plate-specific control used in the calculations. The calculations used in the validation experimental step used an average of pooled measurements from the control treatments from all plates. GraphPad Prism 9 software (GraphPad Software) was used to plot dose-response (D-R) curves and to derive absolute effective concentrations EC10, EC20 and EC50 of %Inhibition and absolute cytotoxic concentrations CC50 of %Cytotoxicity. %Cytotoxicity in the validation experimental step was calculated in THLE-2 human liver and AC16 human cardiomyocyte cell lines. The drugs were added to the wells after the cells were allowed to adhere to the surface for 24 h. The plates were incubated for 72 h before measuring the cell viability via CellTiter-GLO (Promega, G7570) per manufacturer's instructions. %Cytotoxicity calculations in THLE-2 and AC16 were performed using an average of pooled measurements from the control treatments from all plates. IDentif.AI analysis correlated the 6-drug in vitro experimental data into a quadratic series to elicit optimized drug combinations and drug-drug interactions. The analysis was performed in All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.23.21259321 doi: medRxiv preprint MATLAB R2020a (Mathworks, Inc.) (Blasiak et al., 2021) . IDentif.AI analysis derived two quadratic series -%Inhibition, %Cytotoxicity -by including all experimental replicates as inputs and performing bidirectional elimination in which the P value from the F-statistic served as the removal criterion. Box-Cox transformation determined appropriate transformations to improve the residual distributions and the goodness of the fit represented by adjusted R 2 . Residual analysis was performed for each of the two IDentif.AI-derived series. Outlier analysis was performed based on the residual distribution. Interaction surfaces were constructed using drug combinations selected via D-optimal experimental design (N = 9 treatments for EIDD-1931/RDV and EIDD-1931/BRT; N = 6 treatments for EIDD-1931/MST; 3-4 replicates per treatment) performed in MATLAB R2020a (MathWorks, Inc). We assumed a quadratic model of the drug interactions. All replicates were included in the construction of the surfaces. GraphPad Prism 9 software (GraphPad Software) was used to plot D-R curves and derive EC50 of %Inhibition and CC50 of %Cytotoxicity of the validation set treatments (monotherapies and combinations). Drug combinations were tested at two fixed ratios: i) Level 2/Level 2 ratio for EIDD-1931/RDV, and Level 1/Level 2 ratio for EIDD-1931/BRT from IDentif.AI experimental set (OACD ratio); and ii) Cmax/Cmax ratio (Cmax ratio). %Cytotoxicity was evaluated in terms of its effects on the %Inhibition assay. All in vitro experiments were performed in at least 3 biological replicates. %Inhibition and %Cytotoxicity are presented as mean ± propagated standard deviation (SD) (Supplementary Materials and Methods). The IDentif.AI-estimated coefficients were analyzed using sum of squares F-test and P-values for each individual coefficient obtained from stepwise regression. The 12 candidate drugs had hypothesized mechanisms of either inhibiting SARS-CoV-2 entry into the host cell-BRT, NFM, IMT-or inhibiting SARS-CoV-2 replication -EIDD-1931, EBS, SEL, MST, TPV, SN-38, RDV, LPV, RTV (Drayman et al., 2020; El Bairi et al., 2020; Haritha et al., 2020; Kneller et al., 2020; Lovetrue, 2020; Sanders et al., 2020; Sheahan et al., 2020; Stebbing et al., 2020; Xiu et al., 2020) . The antiviral drug effects in monotherapies and in combinations were tested by exposing Vero E6 cells for 72 h to SARS-CoV-2 before measuring the %Inhibition of the virus-induced cytopathic effect (CPE) and the drug toxicity-induced CPE (%Cytotoxicity). The %Inhibition and %Cytotoxicity were derived in independent biological replicates based on different activity ranges, so their effect sizes are not directly comparable. The Z'-factor of 0.569 (N = 52 positive controls and 70 negative controls) indicated that across all three experimental steps, the separation between the negative and positive controls was sufficient to perform an 'excellent' assay (Zhang et al., 1999) . Assay quality details for each experimental step are included in the Supplementary Results. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.23.21259321 doi: medRxiv preprint The first experimental step aimed to gauge the drugs' antiviral activities when the drugs were administered as monotherapies. We exposed the Vero E6 cells with and without the live virus to an increasing concentration of each drug on its own, constructed D-R curves and calculated half maximal absolute effective concentration (EC50) -the drug concentration at which half of the viralinduced CPE is inhibited. An analogical process was performed to understand at what concentration each drug became cytotoxic. Importantly, to ensure the clinical actionability of the findings, the concentration range tested for each drug was selected with consideration of their maximum plasma concentration (Cmax) achieved in the human body (Table 1) to capture the efficacy in a concentration range of interest -clinically actionable concentrations with potential human efficacy. A high Cmax/EC50 ratio indicates a drug's capability to reach the concentrations in the human blood plasma that is sufficient to provide antiviral efficacy (Arshad et al., 2020) . The specifics of the Cmax selection for each drug are presented in the Supplementary Results. The D-R curves ( Fig. S1 ) revealed that the antiviral activities of the drugs were limited when they were administered as monotherapies (Table 1) . RDV and EIDD-1931 were the only drugs that achieved EC50 < Cmax with Cmax /EC50 ratios of 2.92 and 11.46, respectively. RDV, RTV and LPV performance in monotherapy was comparable with that observed in the previous IDentif.AI study based on the same assay (Blasiak et al., 2021) . IDentif.AI was developed as a CDSS for real-world application under pandemic preparedness circumstances, where experimentation is often performed under shortened timelines. In addition, IDentif.AI can be executed in concert with high biosafety level laboratories and specified viral volumes processed per session. While the IDentif.AI 2.0 workflow substantially reduces the time and workload needed for combination design compared to traditional methods, natural biological and experimental variations resulted in an additional study team oversight process in the workflow of narrowing the drug pool based on promising interaction profiles observed from the initial 12drug experiment. This additional step selected RDV, EBS, MST, IMT, BRT and EIDD-1931 to be included in the focused, 6-drug IDentif.AI experimental set that enabled the team to complete the downstream optimization process alongside laboratory guidelines while also minimizing biological and experimental variation. As IDentif.AI 2.0 aims to serve as a CDSS in a real-life setting, its potential for scalable and widespread deployment is a key consideration. In the focused, 6-drug IDentif.AI experimental step, Vero E6 cells with and without the live virus were exposed to the drug treatments in monotherapies and according to a 50-combination Orthogonal Array Composite Design (OACD) table (Table S1 ). The drugs in the treatments had 3 concentration levels (Table 2 ). 10% Cmax for each drug was broadly considered as an achievable dose at the target tissue and served as the maximum concentration level. EIDD-1931 concentration was further restricted to EC20 to avoid overrepresentation of this drug in the experimental set and a potential saturation of the %Inhibition results (Table 2) . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10. 1101 IDentif.AI 2.0 analysis used a quadratic equation to describe the 6-drug interaction space against the SARS-CoV-2 (adjusted R 2 = 0.794; Table S2 ). Monotherapy results demonstrated that EIDD-1931 was the most efficacious drug in the pool, even when given at EC20, with moderate antiviral effects. IDentif.AI 2.0 analysis of the drug-drug interaction detected an unforeseen interaction between EIDD-1931 and RDV, which was the most efficacious two-drug combination, and were predicted to achieve close to maximal %Inhibition in a synergistic interaction demonstrated by the convex shape of the EIDD-1931/RDV interaction surface (Fig. 2 ). In addition, IDentif.AI-derived coefficients pointed to an interaction between EIDD-1931 and BRT. The EIDD-1931/BRT interaction surface had a mildly concave shape across the tested BRT concentration range. BRT was predicted to have a mild antagonistic effect on the EIDD-1931-driven %Inhibition at its midconcentration (Fig. 2) . Little to no cytotoxic effects have been detected in the IDentif.AI experimental step (Supplementary Results). In the IDentif.AI 2.0 validation step we exposed Vero E6 cells to live virus to construct interaction surfaces for EIDD-1931/RDV and EIDD-1931/BRT assuming a quadratic equation. With the focus on a two-drug interaction only, we recalibrated the size of the validated interaction space to range from 0% to 15% Cmax of EIDD-1931 to capture the clinically actionable range (<10% Cmax) and the adjacent space (Fig. 3) . The EIDD-1931/RDV interaction surface had a convex shape pointing to the highest %Inhibition achieved when both drugs are at their highest concentrations, suggesting it is beneficial to provide these drugs in a combination. The flat shape of the EIDD-1931/BRT interaction surface indicated that the %Inhibition results driven by EIDD-1931 are not affected by the presence of BRT. Due to interesting multi-drug behavior observed from IDentif.AI 2.0 analysis, we further assessed the EIDD-1931/MST combination. Of note, IDentif.AI 2.0 analysis did not identify a significant interaction between EIDD-1931 and MST. After expanding the concentration range in the validation set to 15%Cmax of both EIDD-1931 and MST, the concave shape of the EIDD-1931/MST interaction surface indicated that an increase in the concentrations of both drugs could mediate maximum %Inhibition. This phenomenon, however, had the strongest effect outside of the clinically actionable range, potentially explaining why the EIDD-1931/MST interaction was not detected in the IDentif.AI 2.0 step. Given the previously demonstrated immunomodulatory activity of BRT and synergistic potential of MST, the EIDD-1931/BRT and EIDD-1931/MST combinations can potentially be evaluated further, where dose optimization studies may be essential to achieving optimal efficacy. Interaction surfaces were constructed with a small number of drug combination data points and therefore had a limited resolution. To validate IDentif.AI-determined EIDD-1931 interactions with RDV and BRT at a higher fidelity, in the same data set, we included drug treatments to generate D-R curves at the two different drug ratios: as used in the OACD table and dictated by Cmax. The D-R curves revealed additional information. We observed a slight shift in the D-R curves for both combinations: towards a lower and higher EIDD-1931's absolute EC50 for EIDD-1931/RDV All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.23.21259321 doi: medRxiv preprint and EIDD-1931/BRT, respectively (Figs. 3D and E; Fig. S2 ). The mild antagonistic effect of BRT at the OACD ratio is consistent with the IDentif.AI 2.0 analysis. Overall, these results suggest small effect sizes of the tested interactions of EIDD-1931 . Interestingly, at high concentrations, the D-R curve shapes revealed a potential boost in maximum %Inhibition achievable by EIDD-1931 co-administered with RDV or BRT ( Fig. 3D and E; Fig. S3 ). This phenomenon was not observed for EIDD-1931/BRT [OACD ratio] which instead was shown to induce a mildly antagonistic shift in EC50. The observation that the same drug combination at two different ratios can potentially exhibit the opposite interactions points out to the importance of optimizing drug doses at the same time as their combinations. Further experiments are required to confirm and better characterize these observations. The potentially synergistic efficacy interaction demonstrates that combining EIDD-1931 with either RDV or BRT can achieve a higher efficacy than each drug alone, which highlights the potential of EIDD-1931 serving as a backbone to combinational therapies against the SARS-CoV-2. However, as the synergy was detected outside of the actionable interaction space, additional dosing strategies may need to be considered to optimize these interactions in a clinical setting. We retested the efficacy of the pinpointed monotherapies and combination treatments against the SARS-CoV-2 B.1.351 variant. EIDD-1931 and RDV monotherapies demonstrated an increased antiviral activity as compared to the propagated, original strain ( Fig. 4 and S4) . Accordingly, the EIDD-1931 interaction surfaces demonstrated saturation regions at high concentrations of EIDD-1931 and RDV (Fig. 4A) . When %Cytotoxicity was tested in VeroE6, the EIDD-1931/RDV and EIDD-1931/BRT interaction surfaces ( Fig. 5A and B; Fig. S5 ) had a convex shape while the EIDD-1931/MST (Fig. 5C ) had a concave shape indicating that %Cytotoxicity is a result of an interaction between EIDD-1931 and the drugs. However, %Cytotoxicity was low and was not predicted to expand beyond 23% for any of the drug combinations in the actionable range. To gauge the potential cytotoxicity that may be observed in clinical settings, we investigated cytotoxic effects of the EIDD-1931 drug combinations in cell lines of human origin: liver epithelial cells (THLE-2) and cardiomyocytes (AC16). The interaction surfaces had different shapes in different cell lines, highlighting the target-specific cytotoxic characteristics of the treatments. The regular shape of each interaction surface with uniformly high %Cytotoxicity tested at high EIDD-1931 concentration independent of the presence of the other drugs indicate that cytotoxicity in THLE-2 was driven by EIDD-1931 and it was not significantly affected by its interactions with RDV, BRT and MST (Fig. 5D-F; Fig S5) . In AC16 cells, MST did not increase EIDD-1931-driven cytotoxicity; BRT mildly alleviated it in a ratio-dependent fashion; and RDV demonstrated dosedependent cytotoxic synergy, with predicted 29% maximum %Cytotoxicity in the clinically actionable interaction space (Fig. 5G-I; Fig S5) . IDentif.AI 2.0 actionability All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10. 1101 This work has demonstrated IDentif.AI 2.0's potential as a clinically actionable platform to rapidly prioritize drug combinations for further consideration based on high efficacy, and de-prioritize combinations that may be avoided due to lack of efficacy as optimized to a specific SARS-CoV-2 variant. A key technical attribute of IDentif.AI 2.0 is that its combination design workflow is inherently based on optimization via drug and dosing data that are clinically relevant. Our study pinpoints EIDD-1931 to be a promising therapeutic for COVID-19, both as a monotherapy and as the backbone drug for combination therapies. EIDD-1931 is hypothesized to inhibit viral replication by inducing lethal mutagenesis in coronaviruses (Sheahan et al., 2020) . EIDD-2801 (EIDD-1931 has been shown to inhibit SARS-CoV-2 in primary human airway epithelial cell cultures and in multiple animal models (Cox et al., 2021; Rosenke et al., 2021; Sheahan et al., 2020; Wahl et al., 2021) and is currently being evaluated in a Phase 3 trial (NCT04575597). Its ability to be administered orally supports its potential as a rapidly deployable therapy (Merck & Co., 2021) . Additionally, our toxicity results for EIDD-1931 are in line with other studies that have shown that EIDD-2801 may be well-tolerated (Painter et al., 2021; Khoo SH et al., 2021) . The resulting efficacy of the IDentif.AI 2.0 validation combinations indicates that they too may be suitable for further preclinical and/or clinical evaluation with careful dosing adjustment strategy to maximize synergistic efficacy at minimal toxicity. It is important to note that this study was conducted in an in vitro live virus model, and the subsequent preclinical and clinical dose optimization and evaluation will be needed. This study evaluated a pre-specified drug pool, and further studies with additional drug candidates are warranted. Developing a set of drug selection criteria such as drug class, administration route, prior evidence of interaction with other drugs, clinical relevance and accessibility may streamline the development of the drug pool. While the current study did not examine the immunomodulatory effects of the anti-inflammatories (SN-38, BRT), future work using applicable assays towards combination therapy development with immunomodulators is warranted as IDentif.AI 2.0 can be implemented in virtually all assays, provided quantifiable efficacy and toxicity readouts are available. Including immunomodulation will potentially create viable therapeutic options for severe patients as shown by recent clinical progress . The IDentif.AI 2.0 workflow has some technical limitations, nonetheless, it is developed for rapid optimization and clinical actionability, and complementary strategies can be integrated to address them. First, the IDentif.AI interaction space interrogation assumes a quadratic relationship with the efficacy/cytotoxicity responses. The optimized combinations presented here are largely limited to two-drug combinations, rapidly identifying the most significant drugs and its partners from a large drug combination search set. Further development of more complex combinatorial therapy strategies, such as four-or five-drug combinations would likely require some reconciliation of higher-order interactions, similar to previous studies (Tekin et al., 2018) . Second, only limited dosage ratios were tested. Nevertheless, the current results suggest that further preclinical and clinical dosing optimization may reveal the full potential of the pinpointed combination therapies in term of their synergistic potency (i.e., beneficial dose reduction) and synergistic efficacy interactions (i.e., beneficial increase in maximum efficacy) (Meyer et al., 2019) . Additional correlation studies with clinical trial outcomes, when available, will also further determine the applicability of IDentif.AI 2.0 towards go/no-go decisions on combination regimens All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.23.21259321 doi: medRxiv preprint pinpointed by IDentif.AI 2.0. The IDentif.AI 2.0 process in its current form has resulted in promising outcomes, further development of IDentif.AI 2.0 and its potential integration with other methodologies may further enhance its clinical relevance. Clinical decision making in response to the COVID-19 pandemic has been dynamically adapting to new information (Martinez-Sanz et al., 2020; Metlay and Armstrong, 2021) . With new evidence emerging, Infectious Diseases Society of America (IDSA) COVID-19 treatment guidelines provides updated recommendations for certain monotherapies and combinations depending on severity and setting (Bhimraj A, 2021) . Dose optimization has been increasingly recognised as a key therapy optimization element for maximizing public health benefits from the therapeutic solutions of limited supply (Strohbehn et al., 2021) . Therefore, it will be important to pinpoint combination regimens that are clinically actionable, both in composition and dosing parameters based on available recommendations. The IDentif.AI 2.0 platform reported here could provide key insights and address gaps regarding how to optimally combine the therapies. The platform that can rapidly identify treatments for prioritized testing will also be beneficial in the emergence of new viral variants, which potentially affects vaccination and therapeutic efficacies, and also for the treatment of patients that could not be vaccinated, including those who remain ill with evidence of sustained viral replication. Additionally, IDentif.AI can be tailored to generate combinations that address supply chain considerations and local regulations to make the most out of what is available in the geographical and economic feasibility context for a pandemic readiness programme that is inclusive of low-and middle-income countries (LMICs). This work reports the application of IDentif.AI 2.0 towards the rapid optimization and prioritization of combination therapy regimens against COVID-19. The IDentif.AI 2.0 optimization process pinpointed EIDD-1931 /baricitinib, EIDD-1931 /masitinib, and EIDD-1931 /remdesivir as regimens that may be suitable for further evaluation and development. IDentif.AI 2.0 did not rely on pre-existing datasets, synergy predictions, or in silico modeling to design these combinations. Instead, it harnessed data from carefully designed drug-dose permutations and prospectively executed studies to drive the optimization process to complement existing strategies in the fight against COVID-19 pandemic. The promising findings from this work support the expansion of IDentif.AI 2.0 towards a broad range of applications in addressing antimicrobial resistance as well as optimized intervention using antiviral, antibiotic, and antifungal therapies. This work was conducted under study number 2012/00917 approved by the Domain Specific Review Board, as well as approved OSHE/iORC protocol 2020-00494. Tables Table 1 . Drug anti-SARS-CoV-2 efficacy and cytotoxicity when administered in monotherapy as compared to Cmax obtained from the literature and regulatory documents. Absolute EC50 and CC50 were obtained from the D-R curves for each drug individually constructed based on a CPE viral assay with Vero E6 cells. EC curves were plotted after excluding %Inhibition values corresponding to drug concentrations resulting in %Cytotoxicity above 25%. Baricitinib (BRT), ebselen (EBS), selinexor (SEL), masitinib (MST), nafamostat mesylate (NFM), telaprevir (VX-950) (TPV), imatinib mesylate (IMT), remdesivir (RDV), lopinavir (LPV), and ritonavir (RTV). a) EC50 was not achieved within the acceptable cytotoxicity level (below 25%) All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.23.21259321 doi: medRxiv preprint Fig. 2 . IDentif.AI interaction analysis. The analysis indicates that EIDD-1931 interacts differently with remdesivir and baricitinib. EIDD-1931/remdesivir interaction surface had a convex shape indicating a synergistic interaction, while EIDD-1931/baricitinib had a concave interaction surface had a concave shape indicating a dose-dependent, mildly antagonistic interaction. L0, L1, L2 correspond to concentration Level 0, Level 1 and Level 2. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 2, 2021. , baricitinib (BRT) and masitinib (MST) in the validation interaction space, clinically actionable interaction space (black, solid line border) and the interaction space from the IDentif.AI 2.0 analysis (black, dotted line border). The latter two are also shown as 2-dimenisional maps. All experiments were performed with N = 3 to 4 replicates, which were independently included in the surface construction. Black, round markers indicate an average %Inhibition of the replicates for each treatment. Adjusted R 2 (Adj R 2 ) indicates goodness of the fit for each interaction surface. (D-E) Dose-response curves (D-R curves) of EIDD-1931 in monotherapy and in a combination with RDV and BRT at two concentration ratios: the ratio tested in the IDentif.AI 2.0 experimental set (OACD ratio) and the ratio dictated by the Cmax values of the drugs (Cmax ratio). Half maximal absolute effective concentration (EC50) was derived from the D-R curves. The vertical line marks the 10% Cmax of EIDD-1931. Please note that the EIDD-1931-only EC50 values (Green) were provided in both subfigures D and E to enable direct comparisons with both combinations (EIDD-1931/RDV and EIDD-1931/BRT). The entire assay was completed in 1 experiment, realizing all data points in a single global study and enabling comprehensive derivation of combinations and direct comparisons between monotherapies and combinations. Error bars represent propagated SD (N = 3 to 4 replicates). Of note, this propagated SD did not arise from the replicates' spread, but from plate-to-plate variation (SD of the controls). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.23.21259321 doi: medRxiv preprint interaction space (black, solid line border) and the interaction space from the IDentif.AI 2.0 analysis (black, dotted line border). The latter two are also shown as 2-dimenisional maps. All experiments were performed with N = 3 replicates, which were independently included in the surface construction. Black, round markers indicate an average %Inhibition of the replicates for each treatment. Adjusted R 2 (Adj R 2 ) indicates goodness of the fit for each interaction surface. (D) %Inhibition against the propagated, original (black font label, block bar filling) and B.1.351 variants (blue font label, patterned bar filling) of 10% Cmax EIDD-1931 in monotherapy and in a combination with RDV and BRT at two concentration ratios: the ratio tested in the IDentif.AI 2.0 experimental set (OACD ratio) and the ratio dictated by the Cmax values of the drugs (Cmax ratio). The entire assay was completed in 1 experiment, realizing all data points in a single global study and enabling comprehensive derivation of combinations and direct comparisons between monotherapies and combinations. Black markers indicate individual data points. Error bars represent propagated SD. Of note, this propagated SD did not arise from the replicates' spread, but from plate-to-plate variation (SD of the controls). No statistically significant difference was detected with Kruskal-Wallis test when followed by Dunn's post hoc test. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.23.21259321 doi: medRxiv preprint (G-I). (A-I) All experiments were performed with N = 3 to 4 replicates, which were independently included in the surface construction. Black, round markers indicate an average %Cytotoxicity of the replicates for each data point. Adjusted R 2 (Adj R 2 ) indicates goodness of the fit for each interaction surface. Project IDentif.AI: Harnessing Artificial Intelligence to Rapidly Optimize Combination Therapy Development for Infectious Disease Intervention Systematic quantitative characterization of cellular responses induced by multiple signals Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics Remdesivir for the Treatment of Covid-19 -Final Report Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 AI: Rapidly optimizing combination therapy design against severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) with digital drug development Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs Therapeutic MK-4482/EIDD-2801 Blocks SARS-CoV-2 Transmission in Ferrets Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphoma Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro Repurposing anticancer drugs for the management of COVID-19 EMA 2005. Norvir: European Public Assessment Preport -Scientific Discussion Veklury (remdesdivir) EUA Fact Sheet for Healthcare Providers Lessons from the COVID-19 pandemic for advancing computational drug repurposing strategies Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial Dexamethasone in Hospitalized Patients with Covid-19 Ebselen, a new candidate therapeutic against SARS-CoV-2 Artificial intelligence in cancer therapy Enabling Technologies for Personalized and Precision Medicine Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 Harnessing CURATE.AI as a Digital Therapeutics Platform by Identifying N-of-1 Learning Trajectory Profiles Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial Malleability of the SARS-CoV-2 3CL M(pro) Active-Site Cavity Facilitates Binding of Clinical Antivirals Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time Maximizing Efficiency of Artificial Intelligence-Driven Drug Combination Optimization through Minimal Resolution Experimental Design The AI-discovered aetiology of COVID-19 and rationale of the irinotecan+ etoposide combination therapy for critically ill COVID-19 patients Understanding clinical decision-making during the COVID-19 pandemic: A cross-sectional worldwide survey Merck and Ridgeback Biotherapeutics Provide Update on Progress of Clinical Development Program for Molnupiravir, an Investigational Oral Therapeutic for the Treatment of Mild-to-Moderate COVID-19 Clinical Decision Making During the COVID-19 Pandemic Quantifying Drug Combination Synergy along Potency and Efficacy Axes Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19 Repurposing therapeutics for COVID-19: Rapid prediction of commercially available drugs through machine learning and docking Identification and Optimization of Combinatorial Glucose Metabolism Inhibitors in Hepatocellular Carcinomas A computational approach to aid clinicians in selecting anti-viral drugs for COVID-19 trials Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2 Modulating BET Bromodomain Inhibitor ZEN-3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP) Baricitinib as potential treatment for 2019-nCoV acute respiratory disease Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice Harnessing Artificial Intelligence to Optimize Long-Term Maintenance Dosing for Antiretroviral-Naive Adults with HIV-1 Infection Output-driven feedback system control platform optimizes combinatorial therapy of tuberculosis using a macrophage cell culture model Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients Socially optimal pandemic drug dosing Rational, Efficacy-Driven Cancer Drug Dosing via an Artificial Intelligence SystEm (PRECISE): A Protocol for the PRECISE CURATE Prevalence and patterns of higher-order drug interactions in Escherichia coli SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801 Mechanism-independent optimization of combinatorial nanodiamond and unmodified drug delivery using a phenotypically driven platform technology Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities Individualizing liver transplant immunosuppression using a phenotypic personalized medicine platform A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays Prediction of multidimensional drug dose responses based on measurements of drug pairs The authors gratefully acknowledge Associate Professor Justin Jang Hann Chu for helpful discussions. Supplementary material related to this article can be found, in the online version, at doi: XXX